Home > Press > Non-invasive Insulin Delivery to Significantly Improve Diabetes Management
Abstract:
Research and Markets ( http://www.researchandmarkets.com/reports/c48929 ) has announced the addition of Frost & Sullivan's new report: Diabetes Drug Delivery Methods - Market and Technologies to their offering.
Non-invasive Insulin Delivery to Significantly Improve Diabetes Management
DUBLIN, IRELAND | Posted on January 23rd, 2007
This Frost & Sullivan research service titled Drug Delivery for Diabetes-Market and Technologies provides an overview of advancements in drug delivery technologies in diabetes. It also provides a description of the revenues generated by present insulin delivery methods along with a complete analysis of key market drivers, restraints and trends prevailing in the European market. In this research, Frost & Sullivan's expert analysts thoroughly examine the following markets: insulin syringes, insulin pens, insulin pumps and inhaled insulin.
Market Sectors
Expert Frost & Sullivan analysts thoroughly examine the following market sectors in this research:
- Insulin Syringes
- Insulin Pens
- Insulin Pumps
- Inhaled Insulin
Technologies
The following technologies are covered in this research:
- Inhaled insulin
- Oral insulin
- Transdermal insulin
- Nanotechnology
- Diabetes vaccine
- Gene therapy
Market Overview
Non-invasive Insulin Delivery to Significantly Improve Diabetes Management
The growing demand for non-invasive delivery of insulin, particularly inhaled insulin, is leading to increased focus on the diabetes drug delivery market in Europe. Moreover, due to the irregularity exhibited by a significant number of patients in following insulin therapy, companies are pursuing insulin delivery methods that involve reduced pain, thereby facilitating compliance with the therapy. While various non-invasive delivery methods such as oral insulin, transdermal delivery and nanotechnology are still under research, the overall drug discovery market is anticipated to exhibit strong growth.
For diabetic patients using insulin injections, who are faced with issues such as infections, improper administration of insulin and uncontrolled blood glucose, alternate insulin delivery methods are likely to offer tremendous benefits, remarks the analyst of this research service. In addition, with the ability of inhaled insulin to offer glycaemic control comparable to insulin injections, such advantages are likely to promote market growth.
Competitive Pricing Key to Market Growth
Despite the potential of the market, long-term safety and efficacy of pulmonary delivery of insulin are factors expected to pose a challenge to market growth. While the Food and Drug Administration (FDA) as well as the European Medical Evaluation Agency (EMEA) have approved Exubera (the first inhaled insulin to enter the market), occurrences of pulmonary fibrosis during clinical trials are causing concerns about its safety. Hence, pharmaceutical companies involved in the research of inhaled insulin devices will need to focus on long-term safety of emerging insulin delivery methods.
At the same time, novel insulin delivery methods, such as transdermal insulin delivery, are anticipated to gain prominence across Europe The reimbursement of inhaled insulin, which relies on its cost effectiveness as well as patient compliance, is likely to be hampered by its high prices, says the analyst. Hence, the advantages of convenience, safety and accuracy of inhaled insulin in comparison to conventional insulin, will need to be proved to justify the high costs.
####
About Research and Markets
We are the leading source for international market research and market data. We hold ‘000’s of major research publications from most of the leading publishers, consultants and analysts. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends
We are a ‘One-Stop-Shop’ for market research reports and industry newsletters from specialist research firms and niche market analysts.
For more information, please click here
Contacts:
Laura Wood
Fax: +353 1 4100 980
Copyright © Business Wire
If you have a comment, please
Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
Bookmark:
Nanomedicine
How Gold Nanoparticles Can Help Fight Ovarian Cancer May 21st, 2013
MU Researchers Develop Radioactive Nanoparticles that Target Cancer Cells: This is an early step toward developing therapies for metastasized cancers, MU scientist says May 21st, 2013
Nanoparticle Delivers Large Protein Complex to Cancer Cell Nucleus May 20th, 2013
Elsevier Business Intelligence (EBI) to Host 'IN3 Medical Device 360 Boston,' June 24-26, 2013 May 20th, 2013
Announcements
JPK reports on single molecule research at IISER Pune in India using AFM and CellHesion techniques May 21st, 2013
Imec and GLOBALFOUNDRIES collaborate to advance high-density memory technology: STT-MRAM offers enhanced performance and scalability for embedded and standalone applications May 21st, 2013
International survey supports need for built-in water protection on smartphones and tablets May 21st, 2013
Rice unveils method for tailoring optical processors: Arranging nanoparticles in geometric patterns allows for control of light with light May 21st, 2013